New $20M Funding Allows Liquidia to Advance Promising Vaccine Candidate to Clinical Development

Liquidia Technologies, a privately held biopharmaceutical company developing particle-based vaccines and therapeutics, today announced it has completed a $20 million round of Series C financing.

Related Posts

Comments are closed.